University of Aberdeen spin out agrees licence agreement

Elasmogen Ltd, a spin-out from the University of Aberdeen has entered a license agreement with Korea-based ImmunoForge to Elasmogen’s proprietary NDure half-life extension technology for use in two non-disclosed targets. 

[adbutler zone_id=’297765′]

ImmunoForge will be responsible for all pre-clinical and clinical development as well as for manufacturing and commercialisation of the resulting products.  Elasmogen will receive an initial up-front payment in addition to future milestone and royalty payments.

Elasmogen’s NDure albumin binder is based on the company’s soloMER platform. At just 11 kDa, soloMERs are the smallest naturally occurring binding domains.  Their simple molecular architecture facilitates easy combination with a wide range of proteins and peptides to enable rapid development of multi-functional therapeutics.

Caroline Barelle, CEO of Elasmogen said “This licensing agreement provides further validation of the benefits of our soloMER platform and NDure technology. At less than 1/10^th the size of an antibody, NDure allows rapid re-formatting and simple manufacturing while retaining all of the benefits of high specificity albumin binding.

“Using Elasmogen’s proprietary technology, ImmunoForge will develop first-in-class dual hybrid agonists,” said Sung-Min Ahn, CEO of ImmunoForge. “The new dual hybrid agonists will strengthen our sarcopenia pipeline and make new breakthroughs in the treatment of neurodegenerative diseases.”

[yikes-mailchimp form=”2″ title=”1″ description=”1″]